Carver and colleagues showed that PI3K/mTOR inhibition activates AR signaling in human xenograft and transgenic mouse models of prostate cancer, and that co-treatment with the PI3K/mTOR inhibitor BEZ235 and the antiandrogen MDV3100 (enzalutamide) significantly reduced tumor burden relative to monotherapy [11]. Here, PIK3CD is linked to Familial prostate cancer.